| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.10. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder Value | 378 | GlobeNewswire (Europe) | First Patient Dosed with JOTROL Marks Major Clinical Milestone for Jupiter Neurosciences'Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL in Patients with Parkinson's Disease... ► Artikel lesen | |
| JUPITER NEUROSCIENCES Aktie jetzt für 0€ handeln | |||||
| 03.09. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 31.08. | Morning Market Movers: Antelope Enterprise, Jupiter Neurosciences, Wetour Robotics, PG&E Corporation See Big Swings | 1.368 | AFX News | BEIJING (dpa-AFX) - At 7:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 24.08. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 21.08. | Jupiter Neurosciences announces pricing of $2M registered direct offering | 12 | Seeking Alpha | ||
| 21.08. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | 537 | GlobeNewswire (Europe) | New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders... ► Artikel lesen | |
| 14.08. | Top Biotech Gainers: HCTI, LEXX, LNSR, JUNS, OMER, AVAH... | 6 | RTTNews | ||
| 06.08. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | Jupiter Neurosciences executes 1-for-75 reverse stock split | 4 | Investing.com | ||
| 05.08. | Jupiter Neurosciences, Inc. Announces Reverse Stock Split | 385 | GlobeNewswire (Europe) | Jupiter's common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026 JUPITER, FL, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS)... ► Artikel lesen | |
| 28.07. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.07. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Jupiter Neurosciences acquires U.S. rights to ALA-002 in deal worth up to $100M | 2 | Seeking Alpha | ||
| 21.07. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million | 3 | GlobeNewswire (USA) | ||
| 21.07. | PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 | 609 | GlobeNewswire (Europe) | TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 07.07. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson | 382 | GlobeNewswire (Europe) | Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth JUPITER, FL, July 07, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 30.06. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.06. | JUPITER NEUROSCIENCES, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 22.06. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 05.06. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TONIX PHARMACEUTICALS | 2,137 | -1,34 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA | New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial... ► Artikel lesen | |
| BAYER | 53,36 | -2,41 % | Moderna, Bayer, Merck investieren Milliarden - doch bei Psychedelika fehlt ein entscheidendes Teil | ||
| MERCK KGAA | 146,45 | -1,31 % | BERNSTEIN RESEARCH stuft MERCK KGAA auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Merck KGaA von 151 auf 178 Euro angehoben, die Einstufung aber auf "Market-Perform" belassen. Analyst Justin... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 39,240 | 0,00 % | Teva und Neurocrine scheiterten: Schafft NeuroThera jetzt den Tourette-Durchbruch? | ||
| NOVO NORDISK | 34,485 | +0,13 % | Novo Nordisk-Aktie: Value-Falle oder Turnaround-Chance? | Für die Novo Nordisk-Aktie sah es zuletzt wieder deutlich freundlicher aus. Zwar kam es im September noch einmal zu einem kräftigen Rücksetzer, doch seit Anfang Oktober bestimmen die Bullen wieder das... ► Artikel lesen | |
| ELI LILLY | 1.228,80 | -0,07 % | Vom Blockbuster zur Zelltherapie: Wie Eli Lilly und Mesoblast mit neuen Therapien wachsen | ||
| ETON PHARMACEUTICALS | 60,82 | -0,06 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 9,540 | 0,00 % | Generate Biomedicines auf der Jefferies Global Healthcare Conference: Pipeline-Fortschritte und Phase-III-Fokus | ||
| SANOFI | 84,44 | -0,05 % | Dank Organspende zurück ins Leben: Sanofi unterstützt aktuelle Debatte zur Novelle des Transplantationsgesetzes | Frankfurt/Main (ots) - Für viele schwer kranke Menschen ist eine Transplantation die einzige lebensrettende Therapieoption. Ein Spenderorgan kann ihnen den Weg in ein neues, aktives Leben eröffnen.... ► Artikel lesen | |
| PFIZER | 24,960 | -0,20 % | Pfizer vor Neubewertung? Warum Wachstumsmomentum und Bewertung jetzt für Aufmerksamkeit sorgen | Pfizer steht nach Ansicht eines Analysebeitrags auf Seeking Alpha vor einer Phase steigender Gewinne, getragen von einem wieder anziehenden Wachstum im Kerngeschäft und einer aus Sicht des Autors attraktiven... ► Artikel lesen | |
| DERMAPHARM | 32,750 | -2,09 % | Bafin findet Fehler im Dermapharm-Konzernabschluss 2025 | DJ Bafin findet Fehler im Dermapharm-Konzernabschluss 2025
Von Ulrike Dauer
DOW JONES--Die Finanzaufsicht Bafin hat in ihrer seit Juli laufenden Prüfung des Dermapharm-Konzernabschlusses 2025... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,470 | +0,29 % | Aquestive Therapeutics auf Jefferies-Konferenz: Anaphylm treibt das Wachstum voran | ||
| DATAMEDS AI | 1,330 | -0,75 % | Morning Market Movers: DataMEDS AI, Akanda Corp., Solmate Infrastructure, Vision Marine Technologies See Big Swings | MOUNTAIN VIEW (dpa-AFX) - At 7:25 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| APNIMED | 16,090 | 0,00 % | Apnimed, Inc. GAAP EPS of -$1.05 misses by $0.46 | ||
| LB PHARMACEUTICALS | 38,950 | +0,26 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into... ► Artikel lesen |